团队简介
杭州医学院炎症靶点和抗炎药物研发创新团队（以下简称团队）成立于2021年1月，是浙江省“炎症性疾病靶点与新药研究”高水平创新团队，依托杭州医学院药学院进行建设。中心结合药物化学、药理学、分子与细胞生物学等学科，主要从事炎症相关疾病的新靶点、新机制和新药发现研究。现有博士以上研究人员8人（其中国家万人领军1人、优青1人，另有博硕研究生30多人。目前，中心共主持承担国家科技部重点研发专项1项、国家自然基金重点项目1项，面上和青年项目60余项；获授权发明专利18项，公开国际专利2项；在Nat Comm、Circ Res、Diabetes、Nature Chem Bio, TiPS、JMC、BJP等杂志发表高水平论文230余篇。 团队带头人入选Elsevier 2020和2021年度中国高被引学者。团队在国际上首次提出代谢相关分子模式新定义，从“代谢炎症”产生的源头为代谢性疾病提供了新的治疗靶点。科研成果“调控慢性炎症防治代谢性疾病的机制和干预策略研究”获2018年浙江省自然科学一等奖、“以天然药物姜黄素为先导物的系列结构类似物设计与新药发现”获2015年教育部高校科研成果二等奖等；所研发的用于治疗脓毒血症、糖尿病并发症的多个新化合物显示出药理药代和安全性优势，目前已提交了化学1类新药临床试验批件的预申报（pre-IND）。
Target validation and anti-inflammatory drug discovery research group (Hangzhou Medical College) was established in January 2021. This group is mainly focused on drug design, medicinal chemistry, chemical biology, molecular pharmacology, and drug development for the treatment of inflammation and inflammation-mediated metabolic diseases. With the rapid development of our group, it has attracted eight outstanding researchers including one national and two Zhejiang provincial “Thousand Talents Program” distinguished expert, 4 associate professors, as well as more than 30 graduate students. Prof Guang Liang is the leader of this group. Meanwhile, our group has been sponsored by a number of research fundings from the national or provincial sources in the recent years, including more than 40 grants from National Natural Science Foundation of China. To date, more than 230 peer-reviewed papers have been published in the journal of Nat Comm, Circ Res、Diabetes, Nature Chem Bio , TiPS, JMC, BJP etc., accumulating more than 3000 citations.
Group leader was selected as Highly Cited Chinese Scholar by Elsevier in 2020 and 2021. Our group defined these harmful metabolic stimuli as the “metabolism-associated molecular patterns” (MAMPs) for the first time and revealed the mechanism how these MAMPs interact with patter recognition receptors to incite proinflammatory signaling pathways. In addition, our group have obtained 18 authorized Chinese patents in the field of new drug development. Two compounds discovered by our group have demonstrated promising pharmacological application and low toxicity, and now are under the pre-clinical evaluation as anti-inflammatory candidates.